Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients

Basit Öğe Kaydı
dc.authoridBilgic, Mukadder Ayse/0000-0003-0621-8273;
dc.contributor.authorGurel, Ozgul Malcok
dc.contributor.authorYilmaz, Hakki
dc.contributor.authorCelik, Tugrul H.
dc.contributor.authorCakmak, Muzaffer
dc.contributor.authorNamuslu, Mehmet
dc.contributor.authorBilgic, Ayse M.
dc.contributor.authorBavbek, Nuket
dc.date.accessioned2025-10-24T18:08:47Z
dc.date.available2025-10-24T18:08:47Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractGalectin-3 (gal-3) is an emerging prognostic biomarker in heart failure (HF). Clinical and experimental studies suggest that gal-3 is an important mediator of HF. Here we aimed to examine the relationship between gal-3 and diastolic dysfunction in patients undergoing maintenance hemodialysis (HD). We examined the relationship between plasma gal-3 levels and left ventricular diastolic function. Plasma gal-3 was measured in 87 subjects with chronic HD and in 45 healthy controls using biochemical evaluations. Conventional echocardiography and pulsed tissue Doppler assessment were performed in all patients. Left ventricular diastolic dysfunction (LVDD) was defined as E' < 8 cm/s. The E/E' ratio was used as the main determinant of LVDD grade. The mean gal-3 concentrations were: 16.05 ng/ml (13.89-19.75) in healthy controls; 14.54 ng/ml (10.85-17.65) in HD patients with normal diastolic function; and 23.30 ng/ml (20.12-26.87) in HD patients with LVDD (p < 0.01). Plasma gal-3 levels correlated with E/E' (r = 0.933, p < 0.01), left atrial volume index (r = 0.713, p < 0.01), and E' (r = -0.685, p < 0.01). ROC analysis showed that the best gal-3 cut-off point for the diagnosis of LVDD was 20.12 ng/ml with a sensitivity of 67.6 % and specificity of 84.6 % (AUC = 0.803). We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HD patients.
dc.identifier.doi10.1007/s00059-015-4303-6
dc.identifier.endpage794
dc.identifier.issn0340-9937
dc.identifier.issn1615-6692
dc.identifier.issue5
dc.identifier.pmid25990624
dc.identifier.scopus2-s2.0-84939265050
dc.identifier.scopusqualityQ3
dc.identifier.startpage788
dc.identifier.urihttps://doi.org/10.1007/s00059-015-4303-6
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3297
dc.identifier.volume40
dc.identifier.wosWOS:000359742600009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherUrban & Vogel
dc.relation.ispartofHerz
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectGalectin-3; Diastolic dysfunction; Doppler echocardiography; Hemodialysis; Biomarker
dc.titleGalectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients
dc.title.alternativeGalectin-3 als neuer Biomarker diastolischer Funktionsstörung bei Hämodialysepatienten
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu